The next big Alzheimer’s disease study readout is almost here.
Roche is nearing the completion of a pair of clinical trials involving its experimental treatment called gantenerumab. The Swiss pharma giant will announce results from the studies within the next six weeks.
Interest in the readout has heightened since September, when drugmakers Eisai and Biogen announced positive results for lecanemab, their Alzheimer’s treatment. Like gantenerumab, its design is based on the idea that removing toxic brain plaques called amyloid can slow the cognitive decline that characterizes the disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
